Dimephosphone 15% R-R d / oral/oral 100ml FL

Prescription drug

Manufacturer: Татхимфармпрепараты ОАО
Рецептурный препарат
димефосфон 15% р-р д/приема внутрь/наруж 100мл фл
Product is available in pharmacies:
Choose a pharmacy where you would like to pick up the goods
430,00 rub.
+ 9 bonuses на карту
- +
Add to cart
All products in the order are reserved for 24 hours,
after that the order is automatically canceled
Brief information

Производитель

Татхимфармпрепараты ОАО

Действующее вещество

Диметилоксобутилфосфонилдиметилат
There are contraindications, specialist advice is required

The appearance of the product may differ from the photos on the site.

General description
Источник:  РЛС

Composition

Solution for oral and external use100 ml
active substance: 
dimethyloxobutylphosphonyldimethylate15 g
auxiliary substance: purified water-up to 100 ml 

Description of the dosage form

Colorless or yellowish, transparent or opalescent liquid with a peculiar smell.

Pharmacokinetics

Dimephosphone after a single dose is absorbed quite fully, easily penetrates the histogematic barriers and is distributed to various organs and tissues, while C max in the blood is observed within the first hour after administration of the drug; 3 hours after administration, C max is determined in the brain, heart and spleen.

Three days after a single administration of Dimephosphone, only trace concentrations remain in the body.

Dimephosphone is excreted unchanged, mainly in the urine in an amount of 11-15% (up to 70% of the excreted amount is excreted during the first 12 hours). No more than 0.5% is excreted in the feces.

Pharmacodynamics

Dimephosphone exhibits antiacidotic, membrane-stabilizing, anti-inflammatory and antioxidant properties, normalizes blood flow and metabolism of brain tissues, reduces heart and lung failure, and improves the regulation of blood circulation, including brain circulation.

The antiacidotic effect is realized due to the intensification of the renal and pulmonary mechanisms of regulation of CSF, strengthening of intra-organ blood flow and tissue metabolism, and Dimephosphone reduces the content of lactic and pyruvic acids in the brain tissues.

Dimephosphone stabilizes cell membranes, restoring the reactivity of brain vessels, improving the functions of the large hemispheres and the brain stem, reduces the depth of consciousness disorders, restores the sleep—Wake cycle, reflexes, arcs of which are closed through the stem sections, reduces the severity of pyramidal, cerebellar, vestibular, visual and auditory disorders.

The antioxidant effect is carried out by preventing the activation of lipid peroxidation and increasing the activity of antioxidant enzymes in brain tissues.

Dimephosphone enhances energy processes in the brain both directly by acting directly on the mitochondria, and indirectly by stimulating the pituitary-thyroid system, increasing the consumption of thyroid hormones by tissues, which is accompanied by activation of energy and catabolic processes in the mitochondria of cells. It exhibits properties of certain neurotransmitters (GABA-positive, N-choline and dopaminergic activity).

Dimephosphone reduces heart and lung failure by restoring the resistivity of peripheral vessels (arterial and venous).

Dimephosphone improves the regulation of cerebral circulation, without having a pronounced vasodilator effect, but it has a positive effect on the metabolism of brain tissues in their ischemia, improves venous outflow. The effectiveness of clinical use of the drug in various forms of cerebrovascular insufficiency is associated with its ability to increase the resistance of nerve cells to ischemia, with a decrease in edema and, in this regard, improve microcirculation.

When applied topically, Dimephosphone has an anti-inflammatory and antiseptic effect, increases the protective functions of the skin and mucous membranes.

Indications of the drug

Inside, as part of complex therapy:

acute and chronic disorders of cerebral circulation;

consequences of ischemic and hemorrhagic strokes;

traumatic brain injuries;

planned neurosurgical operations;

osteochondrosis;

sclerosis;

chronic non-specific lung diseases with signs of respiratory and pulmonary-heart failure (the use of dimephosphone does not relieve suffocation attacks and does not affect the frequency of use of beta-adrenomimetic aerosols);

vegetative-vascular dystonia of the parasympathetic type;

chronic cerebrovascular insufficiency due to atherosclerosis and hypertension;

migraine;

Meniere's disease;

diseases of the respiratory system;

acidosises;

atopic asthma;

pollinosis.

Outwardly:

infectious-inflammatory-allergic diseases and damage to the skin and mucous membranes: wounds; suture areas and exit points of Ilizarov's spokes; erysipelas;

in dermatology-complex treatment of skin diseases (acne, oily seborrhea, pink acne);

prevention of radiation mucositis.

Contraindications

epilepsy;

chronic renal failure of the 2nd-3rd degree (creatinine Cl less than 40 ml / min);

children and adolescents under 18 years of age-with acute and chronic violations of cerebral circulation, the consequences of ischemic and hemorrhagic strokes, traumatic brain injuries, planned neurosurgical operations, osteochondrosis, multiple sclerosis, chronic non-specific lung diseases with signs of respiratory and pulmonary heart failure, chronic cerebrovascular insufficiency due to atherosclerosis and hypertension, migraine, Meniere's disease;

children under 12 years of age with vegetative-vascular dystonia of the parasympathetic type.

With caution: Dimephosphone is well tolerated by patients. When applied to the mucous membranes, it may cause irritation, in this case it is necessary to dilute The dimephosphone solution twice.

Use during pregnancy and lactation

Currently, data on the use of the drug during pregnancy is not enough to assess the teratogenic effect of Dimephosphone .With this in mind, Dimephosphone should be prescribed during pregnancy and during breastfeeding only if the intended benefit from its use exceeds the potential risk to the fetus or infant.

Animal studies have not revealed a damaging effect on the embryo and its development.

Dosage and administration

Inside, after eating, with water.

The course of treatment depends on the nature of the disease and lasts from 3 days to 2 months.

In the complex therapy of the following diseases and conditions:

In acute and chronic disorders of cerebral circulation, the consequences of ischemic and hemorrhagic strokes, traumatic brain injury-adults 15 ml (1 tablespoon) 3-4 times a day. The duration of the course is 2-3 weeks, in some cases - up to 6 weeks.

For planned neurosurgical operations-15 ml (1 tablespoon) for 5 days before and 2 months after the operation.

For osteochondrosis, adults should take 10 ml (1 des.spoon) 3-4 times a day for 2-3 weeks, improvement is observed on the 8-10 day of treatment.

For multiple sclerosis, adults should take 100 mg / kg (45 ml) per day (15 ml (1 tablespoon) 3 times a day) for 10 days in the autumn-spring period on a monthly basis.

For chronic non-specific lung diseases with signs of respiratory and pulmonary heart failure, adults should take 15 ml (1 tablespoon) 3-4 times a day. The course is 7-10 days. The use of Dimephosphone does not relieve suffocation attacks and does not affect the frequency of use of beta-adrenomimetic aerosols.

For vegetative-vascular dystonia of the parasympathetic type, adults should take 15 ml (1 tablespoon) 3 times a day for 2-3 weeks, and children over 12 years of age should take 50 mg/kg (10-15 ml) 3 times a day for 3 weeks.

In case of chronic cerebrovascular insufficiency due to atherosclerosis and hypertension-15 ml (1 tablespoon) 3 times a day for 2-3 weeks.

For migraines, take 15 ml (1 tablespoon) 3 times a day for 2-3 weeks.

For Meniere's disease-15 ml (1 tablespoon) 3 times a day for 3 weeks.

For respiratory diseases, acidosis, atopic asthma and pollinosis-adults are prescribed 15-25 ml, children are prescribed at a dose of 75-100 mg/kg: up to 3 years — 5 ml (1 teaspoon), 3-8 years — 10 ml (1 des.spoon), older than 8 years-15 ml (1 tbsp. spoon) 3 times a day, in severe cases-4 times a day for 4-5 weeks. When atopic bronchial asthma in combination with pollinosis is prescribed 2-3 weeks before the onset of deterioration and taken during the entire flowering period.

Outwardly.

For infectious-inflammatory-allergic diseases of the skin and mucous membranes - in the form of bandages, turundas and lotions with a solution daily for 3-14 days.

In the complex treatment of acne, wipe the skin 3-4 times a day, in the evening-lotions.

For erysipelas, lubricate the area of inflammation 3 times a day for 3-5 days.

On the area of seams and places of exit of Ilizarov's spokes, gauze napkins impregnated with Dimephosphone are applied daily for 7-14 days.

To prevent radiation mucositis, gauze napkins moistened with Dimephosphone are placed in the projection of radiation beams 20 minutes before exposure of the dose.

Side effect

Dyspeptic phenomena, drowsiness and deterioration of concentration (by the 3rd-4th day of taking the drug pass).

Interaction

Interactions of Dimephosphone with other drugs were not detected.

Overdose

Symptoms: increased severity of dose-dependent side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Special instruction

Influence on the ability to drive a car or perform work that requires increased speed of physical and mental reactions. If you experience drowsiness in the first days of taking the drug, you should refrain from driving vehicles and activities that require increased attention and a high rate of psychomotor reactions.

It has a bitter taste. Children are recommended to drink milk, fruit juice, sweet tea.

Form release

Solution for oral and external use 15%. 100 or 200 ml each in orange or brown glass bottles. The bottle together with the measuring Cup is placed in a pack of cardboard.

Conditions of supply of pharmacies

By prescription.

Manufacturer

JSC Tatkhimfarmpreparaty. 260 Belomorskaya str., Kazan, 420091, Russia.

Tel. (843) 571-85-58; Fax: 571-85-38.

e-mail: marketing@tatpharm.ru

The organization that accepts claims. JSC Tatkhimfarmpreparaty.

The appearance of the product may differ from the photos on the site.

Information about prescription drugs is for professionals only. The information provided should not be used by patients to make an independent decision on the use of the presented drugs and cannot serve as a substitute for a full-time consultation with a doctor.

A description of the active substances of the drug is provided. The scientific information provided is generalized and cannot be used to decide on the possibility of using a specific drug.

To the top